1. Home
  2. Publications & whitepapers
  3. Considerations on Pediatric Investigation Plans (PIP) for Advanced Therapy Medicinal Products

Considerations on Pediatric Investigation Plans (PIP) for Advanced Therapy Medicinal Products

Published on: Oct 10, 2011

 

In Europe, advanced therapy medicinal products (ATMPs) are subject to the requirements laid down in the Paediatric Regulation. A company developing an ATMP must, therefore, obtain agreement from the EMA on a paediatric investigation plan (PIP) or waiver prior to submitting its marketing authorisation application (MAA).

David Uguen, Cecile de Coster
Considerations on paediatric investigation plans for advanced therapy medicinal products, TOPRA Vol 8, No.10

2011 – Regulatory Rapporteur

Download the full resource now
Fill in the form to download the content
Thank you ! Your file is ready to download. Click here to download